Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05611073
Other study ID # JMM-1261
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 7, 2022
Est. completion date November 7, 2022

Study information

Verified date September 2023
Source Berkeley Eye Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This is a non-interventional prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had bilateral implantation of an Eyhance IOL at the time of cataract surgery. These patients will then be compared to assess which patient biometric properties (such as spherical aberration, q value, pupil size, etc.) lead to an overall increase in near or intermediate vision as well as overall patient satisfaction.


Description:

This is a non-interventional prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had bilateral implantation of an Eyhance IOL at the time of cataract surgery. These patients will then be assessed in the 1-6-month post-operative period. Patients will be grouped into two arms: "distance with minimal intermediate" and "distance with enhanced intermediate/near" based on mean photopic binocular BCDVA and DCIVA (at 66 cm) of patients with bilateral Eyhance IOLs corrected to plano sphere. The "distance with minimal intermediate" group is defined by BCDVA of 0.1 logMAR or better but a DCIVA of 0.4 logMAR or worse. The "distance with enhanced intermediate/near" is defined by BCDVA of 0.1 logMAR or better and a DCIVA of 0.3 logMAR or better. In addition to binocular BCDVA and DCIVA, monocular measurements will be obtained as well. The two groups will be compared to assess which patient biometric properties (such as spherical aberration, q value, pupil size, etc.) lead to an overall increase in near or intermediate vision as well as overall patient satisfaction. Biometric data will be obtained from the Zeiss IOL Master 700, Atlas 9000, and the iTrace.


Recruitment information / eligibility

Status Completed
Enrollment 131
Est. completion date November 7, 2022
Est. primary completion date November 7, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: 1. Adults, 40 years of age having already undergone uncomplicated cataract removal by phacoemulsification with a clear corneal incision in both eyes. 2. Implantation of bilateral Eyhance IOLs (DIB00/DIU***). 3. Able to comprehend and willing to sign informed consent and complete all required testing procedures. 4. Best Corrected Distance Visual Acuity (BCDVA) projected to be 0.10 logMAR (Minimum Angle of Resolution) or better. 5. Clear intraocular media. 6. Minimum of two weeks post YAG capsulotomy to treat PCO Exclusion Criteria: 1. Any corneal abnormality, other than regular corneal astigmatism (as determined by pre-operative testing) that in the opinion of the investigator would confound the outcome(s) of the study. 2. Any complication during cataract surgery (capsular tear, vitrectomy, etc.). 3. History of or current retinal conditions or predisposition to retinal conditions. 4. Amblyopia or strabismus in either eye. 5. History of or current anterior or posterior segment inflammation of any etiology. 6. Any form of neovascularization on or within the eye. 7. Glaucoma (uncontrolled or controlled with medication). 8. Optic nerve atrophy. 9. Subjects with diagnosed degenerative eye disorders. 10. Postoperative CDVA worse than 0.10 logMAR (20/25 snellen). 11. Subjects who have an acute or chronic disease or illness that would confound the results of this investigation in the opinion of the investigator (e.g. immunocompromised, connective tissue disease, clinically significant atopic disease, etc.).

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Visual Acuity
Measurement of distance, intermediate and near visual acuity.
Biometric Data Collection
Measurement of biometric data will be obtained from the Zeiss IOL Master 700, Atlas 9000, and the iTrace.
Other:
Patient Questionnaire
Patients will complete a Patient Questionnaire to determine their level of spectacle independence and visual acuity satisfaction.

Locations

Country Name City State
United States Berkeley Eye Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
Berkeley Eye Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Comparison of a patient satisfaction survey between the two groups to assess for subjective differences in everyday life. Patient's answers will be on a scale between always and never, where never shows a better patient outcome. Comparison of a patient satisfaction survey between the two groups to assess for subjective differences in everyday life to determine if the enhanced vision plays a statistically significant difference in patient's perceived quality of vision or quality of life. Patient's answers will be on a scale between always and never, where never shows a better patient outcome. minimum of 3 weeks post operatively
Primary Comparison of two groups categorized by "distance with minimal intermediate" and "distance with enhanced intermediate/near" based on mean photopic binocular BCDVA and DCIVA (at 66 cm) of patients with bilateral Eyhance IOLs corrected to plano sphere. To compare two groups categorized by "distance with minimal intermediate" and "distance with enhanced intermediate/near" based on mean photopic binocular BCDVA and DCIVA (66 cm) of patients with bilateral Eyhance IOLs targeted corrected at plano sphere. minimum of 3 weeks post operatively
Secondary Determine if any statistically significant differences in pupil size exists between the two groups. To determine if any statistically significant differences in pupil size exists between the two groups that may allow for pre-operative recognition of those patients who could have enhanced benefits of the Eyhance IOL. This will require multiple regression analysis given the large number of variables. minimum of 3 weeks post operatively
Secondary Determine if any statistically significant differences in spherical aberration exists between the two groups. To determine if any statistically significant differences in spherical aberration exists between the two groups that may allow for pre-operative recognition of those patients who could have enhanced benefits of the Eyhance IOL. This will require multiple regression analysis given the large number of variables. minimum of 3 weeks post operatively
Secondary Determine if any statistically significant differences in q value exists between the two groups. To determine if any statistically significant differences in q value exists between the two groups that may allow for pre-operative recognition of those patients who could have enhanced benefits of the Eyhance IOL. This will require multiple regression analysis given the large number of variables. minimum of 3 weeks post operatively
Secondary Determine if any statistically significant differences in biometric data exists between the two groups. To determine if any statistically significant differences in biometric data exists between the two groups that may allow for pre-operative recognition of those patients who could have enhanced benefits of the Eyhance IOL. This will require multiple regression analysis given the large number of variables. minimum of 3 weeks post operatively
See also
  Status Clinical Trial Phase
Recruiting NCT01193504 - Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Phase 4
Completed NCT00347243 - Wavefront Analisys and Contrast Sensitivity of Spherical and Aspherical Intraocular Lenses Phase 4
Completed NCT04208633 - Correlation Between Sulcus Anatomy and Other Parameters After Horizontal & Vertical Intraocular Lens (IOLs) Placements N/A
Recruiting NCT06041139 - Visual Outcomes and Patient Satisfaction With Bilateral PanOptix Verses Bilateral Synergy
Completed NCT04533191 - Binocular Custom Vision Utilizing The Light Adjustable Lens (LAL)
Completed NCT05735990 - Retrospective Clinical Investigation of the Safety and Performance of 640PM Trifocal IOL Implantation in Patients With Cataract and/or Ametropia (Hyperopia, Myopia) and/or Presbyopia
Recruiting NCT04175951 - Tecnis Eyhance Versus Rayner RayOne Study N/A
Not yet recruiting NCT06056154 - Safety and Efficacy of the Hydrophobic Intraocular Lens AsqelioTM Monofocal With Biaspheric Design
Not yet recruiting NCT05531110 - Comparison of Two Aspheric Intraocular Lenses for Micro-monovision N/A
Completed NCT01004549 - An Open-Label Evaluation of Degree of Accommodation in Pseudophakic Patients Bilaterally Implanted With Monofocal Intraocular Lenses N/A
Recruiting NCT03823092 - Polarization Perception in Health and Disease. Testing a New Sight Test
Completed NCT05226884 - Intermediate Vision in Patients With Clareon IOLs Compared to Eyhance IOLs
Completed NCT01310127 - Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Phase 4
Completed NCT05335408 - Evaluation of Visual Function After Bilateral Implantation of EDOF IOLs N/A
Completed NCT04319497 - Subjective and Objective Refraction in Pseudophakic Patients N/A
Completed NCT05418153 - Synergy Lens Outcomes Evaluation
Recruiting NCT06065072 - Comparative Study of the Tomey OA-2000, Tomey CASIA2, and the LenStar LS900
Completed NCT02450799 - Corrected VA With Long-Term Follow-Up After AcrySof® Intraocular Lens (IOL) Implantation N/A
Completed NCT00428363 - Effect of Optic Edge Design in a Silicone Intraocular Lens on Posterior Capsule Opacification Phase 4
Completed NCT04468022 - Toric Trifocal IOL Treatment With High Astigmatism and Hyperopia vs SMILE Enhancement After Trifocal IOL Treatment N/A